🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

9 recruiting trials

for Progressive Metastatic Castrate Resistant Prostate Cancer

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) NCT07206056Phase 1, Phase 235 sites📍 Denver📍 Jacksonville📍 Atlanta Novartis Pharmaceuticals · Tests: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer NCT04946370Phase 1, Phase 24 sites📍 Boston📍 Brooklyn📍 New York Weill Medical College of Cornell University · Tests: 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11 Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer NCT07641049Phase 11 site📍 Shenzhen Beijing Biotech · Tests: ETB-DualNK-01, Fludarabine, Cyclophosphamide Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT07871110Phase 216 sites📍 Fuzhou📍 Guangzhou📍 Guangzhou TransThera Sciences (Nanjing), Inc. · Tests: tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib… An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment NCT07538843n/a1 site📍 Multiple Locations Bayer · Tests: Darolutamide, ADT A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC NCT07567521Phase 1, Phase 22 sites📍 Taiyuan📍 Shanghai C Ray Therapeutics · Tests: Radiopharmaceuticals Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 NCT06972628Phase 21 site📍 Houston Ebrahim S Delpassand · Tests: Administering Lutetium-177-PSMA-617 (PLUVICTO) A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer NCT07311694Phase 31 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: HRS-4357 injection, Enzalutamide；Abiraterone Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer NCT04886986Phase 12 sites📍 Brooklyn📍 New York Weill Medical College of Cornell University · Tests: 225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11, 177Lu-PSMA-I&T
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy